Descriptor: "Perflutren -- Intellectual property" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Perflutren -- Intellectual property"' showing total 4 results

Start Over Descriptor "Perflutren -- Intellectual property"

Subjects: Heart diseases, Halofantrine -- Intellectual property, Mirabegron, Trimipramine -- Intellectual property, Sibutramine -- Intellectual property, Tizanidine -- Intellectual property, Amoxapine -- Intellectual property, Posaconazole, Felbamate, Perflutren -- Intellectual property, Terbutaline -- Intellectual property, Antimitotic agents -- Intellectual property, Thioridazine -- Intellectual property, Fosphenytoin -- Intellectual property, Anti-arrhythmia drugs -- Intellectual property, Antipsychotic drugs, Sparfloxacin -- Intellectual property, Lipids, Pentamidine isethionate -- Intellectual property, Nilotinib, Antineoplastic agents -- Intellectual property, Indapamide -- Intellectual property, Rilpivirine -- Intellectual property, Alfuzosin -- Intellectual property, Dolasetron -- Intellectual property, Droperidol, Dexmedetomidine -- Intellectual property, Atazanavir -- Intellectual property, Ivabradine, Hydrochlorothiazide -- Intellectual property, Biotechnology industry, Pharmaceuticals and cosmetics industries, Health
Abstract: 2023 OCT 1 (NewsRx) -- By a News Reporter-Staff News Editor at Heart Disease Weekly -- According to news reporting originating from Alexandria, Virginia, by NewsRx journalists, a patent by [...]
Published: 2023

Subjects: Heart diseases, Halofantrine -- Intellectual property, Mirabegron, Trimipramine -- Intellectual property, Sibutramine -- Intellectual property, Tizanidine -- Intellectual property, Amoxapine -- Intellectual property, Posaconazole, Felbamate, Perflutren -- Intellectual property, Antimitotic agents -- Intellectual property, Terbutaline -- Intellectual property, Thioridazine -- Intellectual property, Fosphenytoin -- Intellectual property, Anti-arrhythmia drugs -- Intellectual property, Antipsychotic drugs, Sparfloxacin -- Intellectual property, Lipids, Pentamidine isethionate -- Intellectual property, Antineoplastic agents -- Intellectual property, Nilotinib, Indapamide -- Intellectual property, Rilpivirine -- Intellectual property, Alfuzosin -- Intellectual property, Dolasetron -- Intellectual property, Droperidol, Dexmedetomidine -- Intellectual property, Atazanavir -- Intellectual property, Ivabradine, Hydrochlorothiazide -- Intellectual property, Biotechnology industry, Pharmaceuticals and cosmetics industries, Health
Abstract: 2023 JUN 4 (NewsRx) -- By a News Reporter-Staff News Editor at Heart Disease Weekly -- A patent by the inventors Augustine, John Kallikat (Bangalore, IN), Bouchard, Annie (Stoke, CA), [...]
Published: 2023

Subjects: Heart diseases, Halofantrine -- Intellectual property, Sibutramine -- Intellectual property, Trimipramine -- Intellectual property, Mirabegron, Tizanidine -- Intellectual property, Amoxapine -- Intellectual property, Povidone -- Intellectual property, Posaconazole, Felbamate, Perflutren -- Intellectual property, Terbutaline -- Intellectual property, Antimitotic agents -- Intellectual property, Thioridazine -- Intellectual property, Fosphenytoin -- Intellectual property, Anti-arrhythmia drugs -- Intellectual property, Antipsychotic drugs, Sparfloxacin -- Intellectual property, Lipids, Pentamidine isethionate -- Intellectual property, Nilotinib, Antineoplastic agents -- Intellectual property, Indapamide -- Intellectual property, Rilpivirine -- Intellectual property, Alfuzosin -- Intellectual property, Dolasetron -- Intellectual property, Droperidol, Dexmedetomidine -- Intellectual property, Atazanavir -- Intellectual property, Ivabradine, Hydrochlorothiazide -- Intellectual property, Biotechnology industry, Pharmaceuticals and cosmetics industries, Health
Abstract: 2022 MAR 20 (NewsRx) -- By a News Reporter-Staff News Editor at Heart Disease Weekly -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a patent application [...]
Published: 2022

Subjects: Heart diseases, Halofantrine -- Intellectual property, Sibutramine -- Intellectual property, Trimipramine -- Intellectual property, Mirabegron, Tizanidine -- Intellectual property, Amoxapine -- Intellectual property, Povidone -- Intellectual property, Posaconazole, Felbamate, Perflutren -- Intellectual property, Terbutaline -- Intellectual property, Antimitotic agents -- Intellectual property, Thioridazine -- Intellectual property, Fosphenytoin -- Intellectual property, Fingolimod -- Intellectual property, Anti-arrhythmia drugs -- Intellectual property, Antipsychotic drugs, Sparfloxacin -- Intellectual property, Lipids, Pentamidine isethionate -- Intellectual property, Nilotinib, Antineoplastic agents -- Intellectual property, Indapamide -- Intellectual property, Rilpivirine -- Intellectual property, Alfuzosin -- Intellectual property, Dolasetron -- Intellectual property, Droperidol, Dexmedetomidine -- Intellectual property, Atazanavir -- Intellectual property, Ivabradine, Hydrochlorothiazide -- Intellectual property, Biotechnology industry, Pharmaceuticals and cosmetics industries, Health
Abstract: 2021 JUL 25 (NewsRx) -- By a News Reporter-Staff News Editor at Heart Disease Weekly -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a patent application [...]
Published: 2021

Books, media, physical & digital resources

Searchworks